CADL · CIK 0001841387
What Candel Therapeutics, Inc. told the SEC could break it.
Candel's register is that of a pre-revenue biotech betting on a single regulatory outcome. It has never sold a product, carries a $230.4 million accumulated deficit, and funds itself with equity and a Trinity term loan secured by substantially all its assets — extending its cash runway into early 2028 after a February 2026 raise. It will not generate meaningful revenue unless and until the FDA approves and it commercializes a product candidate such as aglatimagene; and even then, U.S. drug-pricing policy — including CMS's proposed GLOBE model requiring international-benchmark rebates on sole-source biologics, alongside IRA changes — could pressure the prices it could ultimately charge.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue with $230.4M accumulated deficit and Trinity secured term loanmedium
Candel has never generated product revenue, carries a $230.4M accumulated deficit, and has a $130M Trinity term-loan facility ($50M drawn) secured by substantially all assets; it funds operations via equity/debt and projects cash into Q1 2028 after a Feb 2026 ~$93.5M raise.
“As of December 31, 2025, we had an accumulated deficit of $230.4 million and have not generated any product sales.”
SEC filing →As of 2026
Regulatory & policy
- CMS GLOBE / Medicare drug-pricing rebates on single-source biologicsmedium
CMS's proposed GLOBE model (Medicare Part B) would require manufacturers of single-source drugs and sole-source biologics to pay incremental international-benchmark rebates, which—alongside IRA changes—could pressure prices Candel could obtain for an approved biologic.
“on December 19, 2025, CMS proposed the Global Benchmark for Efficient Drug Pricing Model (GLOBE) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”
Other disclosures
- dependence on FDA approval and commercialization of product candidates (aglatimagene)low
Candel will not generate meaningful revenue unless it obtains FDA approval and commercializes a product candidate such as aglatimagene; failure or delay in approval would leave it without product revenue.
“We will not generate significant revenue from product sales unless and until we obtain regulatory approval and commercialize one of our current or future product candidates.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Ventagen
“Ventagen agreed to purchase from the Company all manufactured product that is required for clinical or commercial purposes at a price of cost plus 25 % of the wholesale price of the approved product, subject to a minimum or maximum price.”
Cited →RTW Investments
“Under the terms of the RTW Purchase Agreement, RTW has agreed to pay us $100 million (the RTW Purchase Price) upon the marketing approval of aglatimagene for the treatment of intermediate-risk and high-risk localized prostate cancer by the FDA in exchange for a tiered royalty on future net sales of aglatimagene in the United States.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch